Dear Dr. Goodrow:

Please refer to your supplemental new drug application dated November 17, 2003, received November 18, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Timoptic XE (timolol maleate ophthalmic gel forming solution) 0.25%, 0.5%.

We acknowledge receipt of your submissions dated March 23, April 9, and July 9, 2004.


This supplemental new drug application provides for a new container/closure system, a new manufacturing site in Mirabel, France, and revised labeling.

We completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

We remind you that the Division should be informed of any out-of-specification (OOS) investigations.

The final printed labeling (FPL) must be identical to the enclosed draft labeling submitted July 9, 2004.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-330/S-018 and S-019.” Approval of this submission by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to
this division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Michael Puglisi, Project Manager, at (301) 827-2090.

Sincerely,

{See appended electronic signature page}

Linda L. Ng, Ph.D.
Chemistry Team Leader for the
Division of Anti-Inflammatory, Analgesic and Ophthalmic Drug Products, HFD-550
DNDC III, Office of New Drug Chemistry Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------
Linda Ng
8/11/04 06:08:01 PM